ClinicalTrials.gg
Not yet recruitingNCT07349134WELL-MPNUpdated Sep 29, 2026

WELL-MPN: A Digital Lifestyle App for Patients With MPNs

An interventional study of WELL-MPN Digital App in Myeloproliferative Neoplasms (MPNs), sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Supportive care

Updated Sep 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs).

The main questions it aims to answer are:

Can people with MPNs use the WELL-MPN app?

Does using the WELL-MPN app improve diet quality and physical activity?

Does the WELL-MPN app improve MPN-related symptoms, anxiety and depression, confidence in managing health, and overall quality of life?

Researchers will compare participants who use the WELL-MPN digital app with participants who receive written educational materials about diet and physical activity for people with cancer to see if the app leads to greater improvements in lifestyle behaviors, symptoms, and well-being.

Participants will:

Be randomly assigned to use the WELL-MPN app or receive written lifestyle education materials

Use the assigned program or materials over the study period

Complete surveys about diet, physical activity, symptoms, mood, confidence in self-care, and quality of life

02

Conditions studied

  • Myeloproliferative Neoplasms (MPNs)

Keywords

  • Myeloproliferative Neoplasms
  • Essential Thrombocythemia
  • Polycythemia Vera
  • Myelofibrosis
03

In context

Myeloproliferative Disorders

667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.

This study's planned enrollment of 75 is above the median of 47 across 462 interventional studies indexed under Myeloproliferative Disorders.

Browse Myeloproliferative Disorders studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,267 studies on the registry; 228 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with a myeloproliferative neoplasm (MPN) by World Health Organization 2016 criteria
  • Adult (age >/= 18)
  • Able to comprehend and speak English
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Unable to comprehend and speak English
  • Unable to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    WELL-MPN Digital App

    WELL-MPN app and usual care

    Behavioral: WELL-MPN Digital App

  • No intervention
    Enhanced Usual Care

    Usual care and written literature about diet and physical activity guidelines in patients with cancer

Interventions

  • BehavioralWELL-MPN Digital App

    Patients randomized to the WELL-MPN arm will be given access to the WELL-MPN digital program (app) which provides lifestyle counseling through an iPad.

06

What researchers measure

Primary outcomes

  1. Number of patients consented and enrolled onto the study, and number of patients who complete at least 2 out of 3 modules in the app.

    Primary outcome is feasibility, defined as ≥60% enrollment of eligible patients and ≥70% of patients randomized to the intervention group completing at least 2 out of 3 of app modules.

    Time frame: 2 years

  2. 8-Item Client Satisfaction Scores (CSQ-8)

    Acceptability of WELL-MPN as measured by CSQ-8 scores of WELL-MPN. The CSQ-8 is a self-report tool designed to measure patient satisfaction with a received intervention. It consists of 8 items rated on a 4-point Likert scale (from "quite dissatisfied" to "very satisfied"), with higher scores indicating greater satisfaction. WELL-MPN is considered acceptable if \>80% of participants on the WELL-MPN arm report a CSQ-8 score \>20.

    Time frame: Enrollment to 16 weeks after enrollment

Secondary outcomes

  1. Healthy Eating Index calculated from the Automated Self-Administered Dietary Assessment Tool

    Diet quality will be compared between control and WELL-MPN patients. The ASA24 is a free 24-hour dietary recall tool developed by the National Cancer Institute. Responses will be used to calculate a Healthy Eating Index (HEI) score, which is a measure of dietary quality that addresses compliance with the 2015 United States Department of Agriculture dietary guidelines (scores range from 0 to 100, with higher scores indicating greater alignment with dietary guidelines).

    Time frame: Enrollment to 16 weeks after enrollment.

  2. Mini Eating Assessment Tool (Mini-EAT) score

    Diet quality will be compared between control and WELL-MPN patients. The Mini-EAT is a 9-item validated brief dietary screener designed for greater ease of administration compared to the ASA-24 but has strong correlation with the HEI. Responses generate a score ranging from 0 to 54, with higher scores reflecting greater adherence to healthy dietary patterns aligned with the Dietary Guidelines for Americans.

    Time frame: Enrollment to 16 weeks after enrollment.

  3. Godin Leisure Time Exercise Questionnaire

    Physical activity will be compared between control and WELL-MPN patients. The Godin Leisure Time Exercise Questionnaire is a brief, self-reported tool used to assess a person's usual physical activity during their free time.It consists of three questions asking information on the number of times one engages in mild, moderate, and strenuous physical activity of at least 15-minute durations in a typical week. Higher scores indicate greater physical activity, with scores of less than 14 units indicating insufficient / sedentary activity.

    Time frame: Enrollment to 16 weeks after enrollment.

  4. Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy Short Forms

    Self-efficacy will be compared between control and WELL-MPN patients. The PROMIS Self-Efficacy Short Forms include 4-item scales across domains such as managing daily activities, symptoms, medications, emotions, and social interactions. Each item is rated on a 5-point Likert scale, with higher scores indicating greater self-efficacy.

    Time frame: Enrollment to 16 weeks after enrollment.

  5. MPN Symptom Assessment Form (SAF) Total Symptom Score (TSS)

    MPN symptom scores will be compared between control and WELL-MPN patients. The MPN SAF TSS is a 10-item questionnaire assessing the most representative and clinically relevant MPN symptoms (concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, fever), and includes a "worst fatigue" question from the Brief Fatigue Inventory. Each subscale ranges from 0 (absent / as good as it can be) to 10 (worst imaginable / as bad as it can be), and scores are computed as the average of the observed items multiplied by 10 to achieve a 0 to 100 scale.

    Time frame: Enrollment to 16 weeks after enrollment.

  6. Hospital Anxiety and Depression Scale (HADS-A and HADS-D):

    Psychological distress will be compared between controls and WELL-MPN patients. The 14-item HADS consists of two 7-item subscales assessing anxiety and depression symptoms in the past week. Each subscale ranges from 0 (no distress) to 21 (maximum distress), with higher scores indicating worse distress. Subscale scores \> 8 indicate clinically significant distress; scores can be further interpreted as follows: 8-10 indicates mild distress, 11-14 indicates moderate distress, and 15-21 indicates severe distress.

    Time frame: Enrollment to 16 weeks after enrollment.

  7. Functional Assessment of Cancer - General (FACT-G)

    Quality of life will be compared between controls and WELL-MPN patients. The FACT-G consists of four subscales assessing well-being across four domains (physical, functional, emotional, and social). Subscale scores include Functional Well-Being (0-28), Social Well-Being (0-28), Emotional Well-Being (0-24), and Functional Well-Being (0-28) with higher scores reflecting better well-being in each domain.

    Time frame: Enrollment to 16 weeks after enrollment.

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Start date
Jun 2026→Jan 2027
Sep 29, 2026
Primary completion
Jan 2029→Jul 2029
Sep 29, 2026
Study completion
Jun 2029→Jul 2029
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Jun 2026→Jan 2027
    Primary completion Jan 2029→Jul 2029
    Study completion Jun 2029→Jul 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07349134
Responsible party
Chi-Joan How, MD (Principal Investigator, Brigham and Women's Hospital) — Principal investigator
First posted
Jan 16, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Chi-Joan How
Contact
jhow@bwh.harvard.edu
617-732-5190
Chi-Joan How
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion